A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

OBJECTIVES: To compare the efficacy and safety of innovator infliximab (INX) and CT-P13, an INX biosimilar, in active rheumatoid arthritis patients with inadequate response to methotrexate (MTX) treatment. METHODS: Phase III randomised, double-blind, multicentre, multinational, parallel-group study....

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Dae Hyun, Hrycaj, Pawel, Miranda, Pedro, Ramiterre, Edgar, Piotrowski, Mariusz, Shevchuk, Sergii, Kovalenko, Volodymyr, Prodanovic, Nenad, Abello-Banfi, Mauricio, Gutierrez-Ureña, Sergio, Morales-Olazabal, Luis, Tee, Michael, Jimenez, Renato, Zamani, Omid, Lee, Sang Joon, Kim, HoUng, Park, Won, Müller-Ladner, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786641/
https://www.ncbi.nlm.nih.gov/pubmed/23687260
http://dx.doi.org/10.1136/annrheumdis-2012-203090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786641/
https://www.ncbi.nlm.nih.gov/pubmed/23687260
http://dx.doi.org/10.1136/annrheumdis-2012-203090

Ejemplares similares